Clinical Guidelines & Documents

Authored and endorsed clinical documents provide three main components vital to advancements in the heart rhythm field: analysis, discussion of current issues, and suggestions for clinical application. The Society plans to release three new documents during the 2017 HRS Scientific Sessions:

  1. 2017 HRS/EHRA/APHRS/ECAS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation
    Scope: An update of the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation that will include recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.
  2. 2017 HRS Expert Consensus Statement on MRI and Radiation Exposure in Patients with CIEDs
    Scope: This document will review the safety considerations and management of the CIED patients requiring imaging. The document will also describe the indications and considerations for MRI-conditional CIEDs, as well as protocols and programming for MRI imaging in patients with CIEDs.
  3. 2017 HRS Expert Consensus on CIED Lead Management and Extraction
    Scope: An update of the 2009 Expert Consensus Statement on Lead Extraction in Patients with CIEDs that will include definitions, identification and management of lead failure, recalls and advisories, indications for lead extraction, periprocedural patient management, facility and operator training considerations, data management, registries and trial design.

Please email should you have questions or need further information.

Volunteer with clinical documents: Contact us at if you are interested in serving as a peer reviewer or writing group member for future clinical documents. Please include your areas of expertise and CV.

Featured Clinical Documents

28108 Beta Blocker Therapy for Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia: Are all beta blockers equivalent?

September 19, 2016 - Drug therapy with beta blockers represents the therapeutic mainstay for both LQTS and CPVT. Our goal is to help clinicians understand the importance of beta blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.

Download the PDF 666.23 kB

24842 SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion

December 10, 2015 - The evolution of LAA occlusion technology has spanned nearly two decades and three FDA panel hearings, leading to FDA approval in 2015. As this technology becomes clinically available to a broader population of patients, it is essential that physician stakeholders establish criteria for the performance of these procedures that will be used in granting initial and ongoing privileges. These criteria are offered to support The Joint Commission mandate that medical staff privileges be granted on the basis of professional criteria specified in the medical staff bylaws to ensure safe and effective patient-centered care.

Download the PDF 242.51 kB